The neuropeptides VIP/PACAP and T cells: Inhibitors or activators?

被引:39
作者
Ganea, D
Delgado, M
机构
[1] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA
[2] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain
关键词
neuropeptides; vasoactive intestinal peptide; pituitary adenylate cyclase activating polypeptide; Th1/Th2 effector cells; macrophages;
D O I
10.2174/1381612033455116
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the expression at both mRNA and protein level of pro-inflammatory cytokines and chemokines, through effects on tic novo expression or nuclear translocation of a number of transcription factors, i.e, NFkB, CREB,C-Jun, IunB, and IRF-1. In addition, VIP and PACAP promote Th2-type, and inhibit Th1-type responses in vivo and in vitro, through several mechanisms, including preferential survival of Th2 effectors and subsequent generation of Th2 memory cells. The function of VIP/PACAP as "macrophage deactivating factors" appears to be responsible For their protective effect in vivo in models of septic shock. Both deactivation of macrophagcs and inhibition of Th1-type responses appear to be responsible for the beneficial effect of VIP/PACAP in models of Th1-type autoimmune diseases such as rheumatoid arthritis.
引用
收藏
页码:997 / 1004
页数:8
相关论文
共 82 条
[1]   Pituitary adenylate-cyclase-activating polypeptide expression in the immune system [J].
Abad, C ;
Martinez, C ;
Leceta, J ;
Juarranz, MG ;
Delgado, M ;
Gomariz, RP .
NEUROIMMUNOMODULATION, 2002, 10 (03) :177-186
[2]   Cytokine and chemokine based control of HIV infection and replication [J].
Alfano, M ;
Poli, G .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (11) :993-1013
[3]   Regulation of VIP release from rat enteric nerve terminals: Evidence for a stimulatory effect of NO [J].
Allescher, HD ;
Kurjak, M ;
Huber, A ;
Trudrung, P ;
Schusdziarra, V .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 271 (04) :G568-G574
[4]   Vasoactive intestinal peptide attenuates cytochrome c translocation, and apoptosis, in rat hippocampal stem cells [J].
Antonawich, FJ ;
Said, SI .
NEUROSCIENCE LETTERS, 2002, 325 (03) :151-154
[5]  
BELLINGER DL, 1990, ANN NY ACAD SCI, V594, P17
[6]   Localization of corticotropin-releasing factor in primary and secondary lymphoid organs of the rat [J].
Brouxhon, SM ;
Prasad, AV ;
Joseph, SA ;
Felten, DL ;
Bellinger, DL .
BRAIN BEHAVIOR AND IMMUNITY, 1998, 12 (02) :107-122
[7]  
Busto R, 2000, ANN NY ACAD SCI, V921, P308
[8]   Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression [J].
Delgado, M ;
Ganea, D .
JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1200-1210
[9]   Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor κB and Ets activation [J].
Delgado, M ;
Ganea, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :31930-31940
[10]   Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages [J].
Delgado, M ;
Ganea, D .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 110 (1-2) :97-105